Latest Biotechnology Capital Management News

Page 1 of 1

Nexalis Therapeutics Links Director Fees to Phase 2 Trial Milestones with Share Rights

Nexalis Therapeutics has issued share rights to directors in lieu of fees, with vesting contingent on successful Phase 2 clinical trial completion, aiming to conserve cash for ongoing drug development.

Ada Torres

14 July 2026

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026